TY  - BOOK
AU  - Prassas,I.
AU  - Diamandis,E.P.
TI  - Novel therapeutic applications of cardiac glycosides
KW  - 7 ETHYL 10 HYDROXYCAMPTOTHECIN
KW  - ANGIOTENSIN RECEPTOR ANTAGONIST
KW  - ANTINEOPLASTIC AGENTAN
KW  - VIRZELBETA ADRENERGIC RECEPTOR BLOCKING AGENT
KW  - BUFADIENOLIDE DERIVATIVEBUFALIN
KW  - CARBOPLATIN
KW  - CARDENOLIDE DERIVATIVE
KW  - CARDIAC GLYCOSIDE
KW  - CINOBUFAGIN
KW  - CISPLATIN
KW  - DIGITALIS
KW  - DIGITALIS EXTRACT
KW  - DIGITONIN
KW  - DIGITOXIGENIN
KW  - DIGITOXIN
KW  - DIGOXINDIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR
KW  - GITOXIN
KW  - LANATOSIDE C
KW  - MARINOBUFAGENIN
KW  - NERIUM OLEANDER EXTRACT
KW  - OLEANDRIN
KW  - OUABAIN
KW  - OXALIPLATIN
KW  - PACLITAXEL
KW  - PROSCILLARIDIN
KW  - UNBS 1450
KW  - UNCLASSIFIED DRUG
KW  - UNINDEXED DRUG
N2  - Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit Na+/K+-ATPase. Members of this family have been in clinical use for many years for the treatment of heart failure and atrial arrhythmia, and the mechanism of their positive inotropic effect is well characterized. Exciting recent findings have suggested additional signalling modes of action of Na+/K+-ATPase, implicating cardiac glycosides in the regulation of several important cellular processes and highlighting potential new therapeutic roles for these compounds in various diseases. Perhaps most notably, the increased susceptibility of cancer cells to these compounds supports their potential use as cancer therapies, and the first generation of glycoside-based anticancer drugs are currently in clinical trials
UR  - https://drive.google.com/file/d/1oIz-uoazEs-9GggBPr1kpQXWWGiQ23G8/view?usp=drivesdk
ER  -